文献速递乳腺癌

GeparSixto最终结果:新辅助化疗加卡铂的生存分析及HRD评分的预测作用

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
PubMed 文献 · Ann Oncol · 2018-01-01

GeparSixto研究在三阴性乳腺癌(TNBC)中评估在紫杉类/蒽环类新辅助化疗基础上加用卡铂的生存获益及同源重组缺陷(HRD)的预后与预测价值。中位随访47.3个月,TNBC患者加用卡铂后无病生存(DFS)显著改善(HR 0.56,95%CI 0.34-0.93;P=0.022),总生存(OS)改善未达统计学显著。HR缺陷独立预测pCR,但HRD并不预测卡铂获益。

要点

  • TNBC加用卡铂显著改善DFS(HR 0.56,P=0.022),OS改善未达显著。
  • HER2阳性肿瘤加用卡铂未改善DFS或OS。
  • HR缺陷独立预测pCR(OR 2.60,P=0.008),但不预测卡铂获益。

核心结论

  • 在TNBC新辅助治疗中,紫杉类/蒽环类方案加用卡铂显著改善DFS,长期生存分析支持卡铂用于TNBC新辅助治疗。
  • TNBC中的HR缺陷及非tmBRCA TNBC中的HRD评分是治疗反应的预测因素,但HRD并不预测卡铂获益。

研究设计与样本

  • GeparSixto为随机研究,患者随机接受紫杉醇联合非聚乙二醇脂质体多柔比星(PM)或PM联合卡铂(PMCb)。
  • 分析次要研究终点DFS和OS,中位随访47.3个月。
  • HRD在193/315(61.3%)例TNBC患者的福尔马林固定石蜡包埋肿瘤样本中成功检测,为探索性分析。

主要发现

  • TNBC患者接受PMCb较PM的DFS显著更优(HR 0.56,95%CI 0.34-0.93;P=0.022),OS改善无统计学意义。
  • HER2阳性肿瘤中加用卡铂未改善DFS或OS。
  • 193例TNBC中136例(70.5%)检出HR缺陷,其中82例(60.3%)为高HRD评分而无tmBRCA。
  • HR缺陷独立预测pCR(ypT0 ypN0)(OR 2.60,95%CI 1.26-5.37,P=0.008)。
  • HR缺陷肿瘤中加卡铂使pCR率由33.9%升至63.5%(P=0.001),HR非缺陷肿瘤中仅由20.0%升至29.6%(P=0.540;交互检验P=0.327)。

关键数值与推荐

  • HR缺陷定义为HRD评分≥42和/或存在肿瘤BRCA突变(tmBRCA)。
  • HR缺陷独立预测pCR:OR 2.60,95%CI 1.26-5.37,P=0.008。
  • HR缺陷肿瘤加卡铂pCR率33.9%→63.5%(P=0.001);HR非缺陷肿瘤20.0%→29.6%(P=0.540;交互P=0.327)。
  • 高HRD评分无tmBRCA者加卡铂pCR率63.2% vs 31.7%(OR 3.69,95%CI 1.46-9.37,P=0.005)。

临床怎么用

  • TNBC新辅助治疗可考虑在紫杉类/蒽环类方案基础上加用卡铂以改善DFS。
  • HR缺陷或高HRD评分(无tmBRCA)的TNBC患者pCR率更高,可辅助评估治疗反应预期。
  • HRD状态不宜用于筛选卡铂获益人群,因HRD并不预测卡铂获益。

局限性

  • HRD分析为探索性分析,仅61.3%(193/315)的TNBC患者样本成功检测。
  • HRD检测限于TNBC亚组,HER2阳性人群未纳入HRD分析。
  • OS改善未达统计学显著,生存分析需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Here, we present survival data and the potential prognostic and predictive role of homologous recombination deficiency (HRD). PATIENTS AND METHODS: Patients were randomized to paclitaxel plus nonpegylated liposomal doxorubicin (Myocet®) (PM) or PM plus carboplatin (PMCb). The secondary study end points disease-free survival (DFS) and overall survival (OS) were analyzed. Median follow-up was 47.3 months. HRD was among the exploratory analyses in GeparSixto and was successfully measured in formalin-fixed, paraffin-embedded tumor samples of 193/315 (61.3%) participants with TNBC. Homologous recombination (HR) deficiency was defined as HRD score ≥42 and/or presence of tumor BRCA mutations (tmBRCA). RESULTS: A significantly better DFS (hazard ratio 0.56, 95% CI 0.34-0.93; P = 0.022) was observed in patients with TNBC when treated with PMCb. The improvement of OS with PMCb was not statistically significant. Additional carboplatin did not improve DFS or OS in patients with HER2-positive tumors. HR deficiency was detected in 136 (70.5%) of 193 triple-negative tumors, of which 82 (60.3%) showed high HRD score without tmBRCA. HR deficiency independently predicted pCR (ypT0 ypN0) [odds ratio (OR) 2.60, 95% CI 1.26-5.37, P = 0.008]. Adding carboplatin to PM significantly increased the pCR rate from 33.9% to 63.5% in HR deficient tumors (P = 0.001), but only marginally in HR nondeficient tumors (from 20.0% to 29.6%, P = 0.540; test for interaction P = 0.327). pCR rates with carboplatin were also higher (63.2%) than without carboplatin (31.7%; OR 3.69, 1.46-9.37, P = 0.005) in patients with high HRD score but no tmBRCA. DFS rates were improved with addition of carboplatin, both in HR nondeficient (hazard ratio 0.44, 0.17-1.17, P = 0.086) and HR deficient tumors (hazard ratio 0.49, 0.23-1.04, P = 0.059). CONCLUSIONS: The addition of carboplatin to neoadjuvant PM improved DFS significantly in TNBC. Long-term survival analyses support the neoadjuvant use of carboplatin in TNBC. HR deficiency in TNBC and HRD score in non-tmBRCA TNBC are predictors of response. HRD does not predict for carboplatin benefit.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Loibl S, Weber KE, Timms KM, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol. 2018. PMID: 30335131. doi:10.1093/annonc/mdy460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。